| Similar Articles |
|---|
 |
Bio-IT World
January 13, 2003
Michael Greeley |
What Do We Do Now? Like it or not, the supply of capital is an important ingredient in the continued development of the bio-IT industry. Appreciating and understanding the forces currently at work in the VC marketplace can only help in raising capital.   |
Bio-IT World
May 9, 2003
Michael Greeley |
Mechanistic Models Investors are backing predictive modeling software that could speed drug development. |
Bio-IT World
September 11, 2003 |
Show Me the Evidence ... Some emerging bio-IT services companies are beginning to attract venture capital. |
Bio-IT World
March 10, 2003
Michael Greeley |
Too Much Informatics Did bioinformatics companies forget about the fundamental law of supply and demand? |
Bio-IT World
July 15, 2003
Michael Greeley |
Finally, the Bottom Has pharma bought all the solutions it needs? The flood of genomic data indicates no. |
Bio-IT World
October 10, 2003 |
Funds Up Venture financing numbers are in for Q2, and the news is not all bad. |
Bio-IT World
Dec 2005/Jan 2006
Michael A. Greeley |
Infinite Demand for the Unavailable The bio-IT field is once again attracting venture capital, but at a more moderate, deliberate pace than the euphoria of the late 1990s. |
Bio-IT World
March 17, 2004 |
Signs of Spring Colin Hill, CEO of Gene Network Sciences, a predictive systems biology company, says the worst is behind the bio-IT industry. "The hype has dissipated, and companies are focused on delivering the results," he says. Hill's strategy includes developing additional products, which should generate near-term revenue. |
Bio-IT World
October 14, 2004
Michael Greeley |
Go East Business is great in China, and the government is strongly encouraging the local biotech industry. |
Bio-IT World
August 13, 2003
Michael Greeley |
Two Cents on the '$1,000 Genome' Are venture capitalists still looking for 'the killer app'? Funding the next big idea won't be so easy. Affordable, individualized genome sequencing holds great promise, but making the claims sound too grandiose can be dangerous. |
Bio-IT World
February 10, 2003
Michael Greeley |
The Upside of the Downturn Biotech entrepreneurs need to rethink how they raise capital and craft business model frameworks. |
Bio-IT World
April 2006
Michael A. Greeley |
The Good, The Bad, and The Ugly VCs will not support a sector where consistent compelling exits are not evident. Unfortunately, the bio-IT field still suffers from this. |
Bio-IT World
January 12, 2004
Michael A. Greeley |
What You See Is What You Get Better image analysis, better business models. The transition from analog to digital will allow systems biology to reach its full potential. |
Bio-IT World
Jul/Aug 2006
Michael A. Greeley |
Monsoon of Capital The private equity markets, both venture capital and growth equity, while characterized by a number of established firms, continue to struggle with how best to finance early-stage, risky bio-IT companies. |
Bio-IT World
November 14, 2003
Michael Greeley |
Show You the Money Venture capitalists need to balance two, at times conflicting, parameters when considering compensation for the executives at biotech companies in their portfolios: cash and long-term equity incentives. |
Bio-IT World
June 12, 2002
Morris R. Levitt |
A New Economic Paradigm for Bio-IT? All who work in the bio-IT industry -- scientists, IT and informatics managers, and executives -- have been aware for some time that we seem to be suspended between an acute sense of crisis and a field of boundless opportunity. |
Bio-IT World
September 16, 2004
Michael A. Greeley |
Platforms for Pathways Investor interest in the next great blockbuster drug has been blistering hot; Phase II and Phase III compound companies are being funded at a near record-breaking pace now that the IPO window seems to be slightly open |
Entrepreneur
April 2009
Brad Feld |
Beware the Arrogant Venture Capitalist Their weaknesses may vary, but there's typically a common characteristic not-great venture capitalists share: arrogance. |
Wired
April 2004
Gary Rivlin |
The Roots of Bust 2.0 Suddenly, venture capital is growing on trees. But the cash glut could crash the Valley again. |
Entrepreneur
February 2009
Brad Feld |
VC vs. Angel Money: A Primer Don't blow a financing opportunity by approaching the wrong source. |
Bio-IT World
December 15, 2003
Michael Greeley |
Tiny Devices, Big Opportunities Parallel advances in drug formulation and microprocessing and other manufacturing technologies are creating new products and services as these industries start to intersect. |
Bio-IT World
June 2005
Michael A. Greeley |
Who Wants to Be a VC? The objective is to stay relevant to a venture firm while the industry contracts. Develop the case that you can help create great companies (and great returns) because you have built a Rolodex and an ability to identify patterns of success. |
Entrepreneur
February 2009
Guy Kawasaki |
Top 9 Lies of Venture Capitalists Here's a look at the meanings behind what VCs say. |
Entrepreneur
July 2008
David Worrell |
It's Go Time When times are tough, look to non-bank lenders for venture debt. |
Entrepreneur
July 2002
Mark Henricks |
Answering the Call Trust corporations to know when the VC game is ready for new players. |
Entrepreneur
January 2009
Brad Feld |
Perfect Your Pitch If you want to secure venture capital, avoid these 8 mistakes. |
Entrepreneur
August 2008
Carol Tice |
On the Horizon The economy may be down, but the expansion capital outlook remains positive in 2008. |
Bio-IT World
May 19, 2004
John Russell |
Informatics Black Boxes ... Not! Vertex's chief technical officer, discusses informatics' bad reputation, buying vs. building, open-source tools, and ROI on IT. |
Bio-IT World
March 8, 2005
Michael A. Greeley |
What's New at Big Blue? The scale of computing has improved dramatically in the life sciences. But has the bio-IT industry over-promised, and does it risk under-delivering? Ultimately, customers will want to see a return on these investments, and that won't happen in two to three years. |
Bio-IT World
June 2006
Michael A. Greeley |
Backwards Influence Biotech companies must think downstream as they consider what drugs to develop. Many companies are introducing cost-effectiveness analysis earlier in the discovery process. |
Entrepreneur
April 2007
Guy Kawasaki |
Go for the Gold If you're trying to get venture capital, follow these 10 steps to impressing investors, and you'll be on your way to the big time. |
Bio-IT World
September 2005
Michael A. Greeley |
Harvesting Patient Data Longitudinal data tools will allow pharmaceuticals to optimize sales force deployments and distribution strategies based on medical impacts of their compounds across various population sets. |
Entrepreneur
August 2008
Tracy T. Lefteroff |
High Rollers Venture capitalists showed entrepreneurs the big bucks in 2007. Could one of our top VC firms be looking for a business like yours this time around? |
Entrepreneur
April 2010
Brad Feld |
Know When to Walk Away Don't ask venture capitalists for referrals if they say they're not interested. |
| Knowledge@Wharton |
Venture Capitalists: More Caution, More Due Diligence, More Diversity Venture money is out there, but it will be staying more and more with entrepreneurs who have better grounding, better products and at least a modicum of a track record... |
HBS Working Knowledge
February 2, 2009
Sarah Jane Gilbert |
The Success of Persistent Entrepreneurs When it comes to entrepreneurship, nothing says success like a track record of previous wins. |
Entrepreneur
April 2009
Asheesh Advani |
Know How Your VC Gets Paid The bear market brings several implications for startups looking for funding. |
InternetNews
November 5, 2009 |
Startup Software Spending Falls to 13-Year Low Investment in fledgling software companies reaches its lowest level in 13 years as clean tech and biotech spending surges. |
Entrepreneur
July 2003
Lefteroff et al. |
The Thrill of the Chase Nowadays, it seems venture capitalists are an endangered species, but your chances of finding VC funding are better than you think. We'll help you track down investors with our 3rd Annual VC 100. |
The Motley Fool
September 16, 2005
Rich Smith |
Are You a Venture Capitalist? Then stop investing as though you've got money to burn. The way to make money in stocks is to invest in financially sound, responsibly managed, profitable companies. |
Entrepreneur
July 2002
Tracy T. Lefteroff |
After The Flood With the flow of VC funding slowed to a trickle, let our list of the top 100 VC funds be your divining rod. |
Bio-IT World
July 11, 2002
Kevin Davies |
Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go. |
Fast Company
March 2000
Fast Company |
Built to Last Fast Company issues this call to action and invites you to read it, sign it, and join the movement to realize the promise of the new economy. |
Bio-IT World
July 2005
Michael A. Greeley |
CEO Lessons on Product and Market In the face of extraordinary R&D budgets generated by biopharma industries, bio-IT companies must refine their value propositions in the hopes that meaningful (predictable and repeatable) revenue streams can be created. |
Pharmaceutical Executive
September 1, 2010 |
Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development. |
Salon.com
July 19, 2000
Janelle Brown & Katharine Mieszkowski |
Score: Men 97, Women 3 Men entrepreneurs still receive almost all the venture capital. What will it take for women to catch up? |
The Motley Fool
December 21, 2010
Brian Orelli |
4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday. |
Entrepreneur
January 2008
Guy Kawasaki |
Garnering Angels Sure, you may have ventured for VC, but raising angel capital takes a different kind of skill. |
Inc.
May 1, 2010
Bobbie Gossage |
An Insider's Guide to Venture Capital Financing Jeffrey Bussgang, author of Mastering the VC Game and a principal at Flybridge Capital Partners, on how to get funded. |
InternetNews
November 5, 2010 |
VC Spending Plummets But Software Still Tops The third quarter was a disappointing one for venture capital investment but a good number of new software companies have little to complain about. |
